ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Zhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*南方医科大学
PROSTATE2023-11DOI: 10.1002/pros.24607
7阅读
引用收藏
分享

摘要

BackgroundAndrogen deprivation therapy (ADT) is one of the main treatment modalities for prostate cancer (PCa); however, almost all patients treated with ADT eventually progress into castration-resistant PCa (CRPC). Although second-generation androgen receptor (AR) antagonists, such as enzalutamide, have been approved for CRPC treatment, AR signaling in CRPC cells is reactivated through multiple mechanisms, resulting in resistance to treatment and tumor progression with a very poor prognosis. The present study aimed to explore the anticancer effect of a treatment combining AR antagonist enzalutamide with AR degrader IU1 on PCa cells. MethodsThe joint effects of enzalutamide and IU1 on PCa cell proliferation and apoptosis and associated cell signaling were evaluated in vitro. Mechanistically, the ubiquitination level and half-life of AR were examined under the combination treatment. The binding of IU1 and enzalutamide to AR was further verified using cellular thermal shift analysis and isothermal dose-response curve fingerprinting. ResultsThe combination of IU1 and three AR antagonists showed synergistic effects in different prostate cell lines. IU1 and enzalutamide synergistically promoted the degradation of AR and AR-V7 proteins, as well as suppressed the expression levels of AR and AR-V7 downstream target genes at the transcriptional and protein levels. The combination also synergistically blocked the PCa cell cycle and promoted apoptosis in PCa cell lines. Mechanistically, the combination promoted increased levels of AR ubiquitination. In CRPC cell lines and in the presence of increased androgen concentrations, enzalutamide was still able to bind AR competitively with androgens, reducing the stability of AR and thus promoting the degradation effect of IU1 on AR, synergistically producing an inhibitory effect on PCa cells. ConclusionTaken together, our findings suggest that the combination of AR degrader and enzalutamide potentially represents a new therapeutic strategy for CRPC.

学科与关键词

关键词
androgen receptor antagonistscastration-resistant prostate cancerenzalutamideIU1ubiquitination
相关
加载中…
  • Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Luo, Mayao; Zhang, Yifan; Xu, Zhuofan; Wu, Chenwei; Ye, Yuedian; Liu, Rui*; Lv, Shidong*; Wei, Qiang*Cell Death Discovery, 2022, 8(1): 471.被引 1
  • Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
    Cong, Xiaonan; He, Yundong; Wu, Haigang; Wang, Dingxiang; Liu, Yongrui; Shao, Ting; Liu, Mingyao; Yi, Zhengfang; Zheng, Jianghua; Peng, Shihong*; Ding, Tao*Frontiers in Oncology, 2021, 11: 650919.被引 4
  • Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer
    Feng, Yuanfa; Deng, Yulin; Tang, Zhenfeng; Cai, Shanghua; Li, Jinchuang; Liu, Ren; Wan, Jiaming; He, Huichan; Zeng, Guohua; Ye, Jianheng*; Han, Zhaodong*; Zhong, Weide*Frontiers in Endocrinology, 2023, 14: 1148898.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
PROSTATE
发表日期
2023-11
卷期
第 83 卷, 第 15 期
页码
1446-1457
DOI
10.1002/pros.24607
语言
ENGLISH
成果收录
SCIE
资助标注
Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University [2021J005]; Presidential Foundation of Nanfang Hospital, Southern Medical University [2020C017]; National Natural Science Foundation of China [82103276]; Natural Science Foundation of Guangdong Province [2021A1515011023]; Guangzhou Science and Technology Programme [202201011526]

作者

  • Z

    Zhang, Yifan (第一作者)

    southern med univ

  • L

    Liao, Yuanpeng

    southern med univ

查看全部 10 位作者收起作者
  • L

    Luo, Mayao

    southern med univ

  • Y

    Ye, Yuedian

    southern med univ

  • X

    Xu, Zhuofan

    southern med univ

  • H

    Hou, Wenli

    southern med univ

  • L

    Liu, Ruiyu

    southern med univ

  • Z

    Zhai, Qiliang

    southern med univ

  • L

    Lv, Shidong (通讯)

    southern med univ

  • W

    Wei, Qiang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417